2020
DOI: 10.5603/pjnns.a2020.0070
|View full text |Cite
|
Sign up to set email alerts
|

Role of gadolinium-based contrast agents in neurological disorders

Abstract: Gadolinium-based contrast agents (GBCAs) are widely used in magnetic resonance imaging (MRI) to help with the diagnostic and monitoring processes of many diseases, including neurological disorders. Initially, it was assumed that GBCAs carry minimal risk, are safe and well tolerated. But recent reports of GBCA-associated deposition in many body tissues have raised concerns about the broader health impacts of gadolinium exposure. The aim of this review was to summarise knowledge regarding gadolinium deposition, … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
9
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(9 citation statements)
references
References 94 publications
0
9
0
Order By: Relevance
“…Recently, gadolinium deposition in the brain has drawn attention, 25 although newer macrocyclic gadolinium agents lower the risk of depositions compared with older linear gadolinium agents 26,27 and the long-term clinical implications are unknown. 25,28 Although gadolinium can be used to better demonstrate SEGAs, in light of the need for repeated scans during childhood and potential side effects of contrast agents, combined with noncontrast imaging sequences generally sufficient for screening for SEGA, we recommend avoiding contrast agents until there is a growing lesion or clinical suspicion of SEGA. In the latter circumstances, gadolinium can better define the lesion size, characteristics, and margins and nearby anatomical structures, which may be important for decision-making and for planning and monitoring treatment response.…”
Section: Brainmentioning
confidence: 99%
“…Recently, gadolinium deposition in the brain has drawn attention, 25 although newer macrocyclic gadolinium agents lower the risk of depositions compared with older linear gadolinium agents 26,27 and the long-term clinical implications are unknown. 25,28 Although gadolinium can be used to better demonstrate SEGAs, in light of the need for repeated scans during childhood and potential side effects of contrast agents, combined with noncontrast imaging sequences generally sufficient for screening for SEGA, we recommend avoiding contrast agents until there is a growing lesion or clinical suspicion of SEGA. In the latter circumstances, gadolinium can better define the lesion size, characteristics, and margins and nearby anatomical structures, which may be important for decision-making and for planning and monitoring treatment response.…”
Section: Brainmentioning
confidence: 99%
“…Neuroimaging employs imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) to assess the structure and function of the CNS, diagnose diseases, determine prognosis and proper treatments, and plan or guide surgical interventions [ 1 5 ]. CT detects how X-rays differentially traverse and attenuate through fluids and tissues to construct a series of cross-sectional images in three planes, allowing for synthesis of a three-dimensional image [ 6 , 7 ].…”
Section: Introductionmentioning
confidence: 99%
“…The use of gadolinium‐based contrast agents (GBCA) to aid in MRI of brain lesions dates back to 1988 in humans and remains a widely accepted, relatively safe procedure 1 . .…”
Section: Introductionmentioning
confidence: 99%
“…. 2 Adverse events in humans are generally mild with life‐threatening anaphylactic reactions reported in 0.001% to 0.01% of administrations 1 . The role of GBCA in nephrogenic systemic fibrosis in humans was established in 2006, but the effects on the brain are uncertain despite evidence of long‐term gadolinium deposition within certain areas of the brain 1,2 .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation